ebook Munafa Stock Market Course + Intraday & FNO calls  

       

SW0C announcements S&p Developed Ex-u.s.bmi [capped] announcements and dividends declared INDICES

S&p Developed Ex-u.s.bmi [capped] Complete list of announcements declared & dividend announcements by S&p Developed Ex-u.s.bmi [capped] SW0C

S&p Developed Ex-u.s.bmi [capped] SW0C listed on INDICES and deals in

Announcements and dividends declared by S&p Developed Ex-u.s.bmi [capped] SW0C

18 lakh passengers caught, Rs 140.8 crore recovered: Railways intensifies checks as penalty earnings jump 40% in just 5 months
Central Railway recovered Rs 140.8 crore in penalties from 18 lakh ticketless and unauthorised travel cases between April and August, marking a 40% rise from the same period last year. Mumbai division recorded the highest collection at Rs 58.5 crore, while
Announcement as on 21 September 2026

Tata Motors Passenger Vehicles allots 1 lakh equity shares under ESOP
Consequent to the aforesaid allotment, the paid-up equity share capital of the Company stands increased to Rs 7,36,64,61,785 divided into 3,68,29,92,140 equity shares of Rs 2/- each (considering the amount of subscribed share capital plus shares forfeited
Announcement as on 21 September 2026

Indian Oil to invest 6 mn for Kochi-Thoothukudi natural gas pipeline
The investment comes amid India's broader push ?to expand natural gas ?infrastructure, improve connectivity and increase the ?share of gas in the country's energy mix as it ?seeks ?cleaner fuel altern
Announcement as on 21 September 2026

IOCL to invest ?2,449 cr in Kochi-Kanyakumari-Thoothukudi gas pipeline
The 424.5-km pipeline will have a capacity of 6.84 mscmd and transport regasified LNG from the Kochi terminal to key demand centres in Kerala and Tamil Nadu
Announcement as on 21 September 2026

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo
Biocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The European Commission will take the final decision on marketing authorisation acro
Announcement as on 21 September 2026

Announcements by S&p Developed Ex-u.s.bmi [capped] first page | Next page | Prev page |

SW0C S&p Developed Ex-u.s.bmi [capped] current price & indicator signals

Moving Averages for S&p Developed Ex-u.s.bmi [capped]

  • 5Day Average: 133.15
  • 12Day Average: 134.55
  • 20Day Average: 135.4
  • 50Day Average: 140.4
  • 100Day Average: 137.06
  • 150Day Average: 136.9
  • 200Day Average: 136.76

SW0C Indicators & signals

Indicator MACD (12,26,9)

134.51, 136.34, -1.8
Indicator MACD is in negative zone

Indicator ADX (14)

17.24, 22.43, 31.78
Indicator ADX is indicating that momentum is weak.
Momentum is towards selling.

Indicator RSI (14)

Current RSI is: 48
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of SW0C S&p Developed Ex-u.s.bmi [capped] are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
19 Mon Oct 2026 133.80 133.31 to 134.68 -0.44% 0 times
16 Fri Oct 2026 134.39 133.09 to 135.23 1.5% 0 times
15 Thu Oct 2026 132.41 130.48 to 132.70 0% 0 times
15 Thu Oct 2026 132.41 130.48 to 132.70 -0.24% 0 times
14 Wed Oct 2026 132.73 132.57 to 135.66 -1.67% 0 times
13 Tue Oct 2026 134.99 134.57 to 136.08 -0.63% 0 times
12 Mon Oct 2026 135.85 135.73 to 136.65 0.05% 0 times
09 Fri Oct 2026 135.78 133.61 to 136.06 1.34% 0 times
08 Thu Oct 2026 133.98 133.03 to 134.50 -0.7% 0 times
07 Wed Oct 2026 134.93 134.42 to 137.31 -1.67% 0 times
06 Tue Oct 2026 137.22 136.01 to 137.61 0.85% 0 times
05 Mon Oct 2026 136.07 134.93 to 136.38 0.33% 0 times

Videos related to: SW0C announcements S&p Developed Ex-u.s.bmi [capped] announcements and dividends declared INDICES

Hindi Video Most Important Stock Market Video. No Success Without This Formula

Hindi Video What Is Needed To Succeed In Stock Markets

SW0C announcements S&p Developed Ex-u.s.bmi [capped] announcements and dividends declared INDICES

 

Back to top